Patents Represented by Attorney Licata & Tyrrell P.C.

Find this attorney in the Justia Lawyer Directory

  • Calbindin-Dprotection against glucocorticoid induced cell death
    Patent number: 7790155
    Abstract: The present invention provides novel compositions containing a calbindin-D28k therapeutic element, which is involved in the regulation of apoptosis, and may be administered for the prevention of an abnormal apoptosis response in cells. In particular the compositions and methods of the present invention may be used for the prevention or induction of apoptosis in such cells types as osteoblasts and osteocytes. Specifically, the compositions and methods of the present invention are useful for the prevention of diseases associated with glucocorticoid induced cell death. Specifically, the compositions and methods of the present invention may be useful in the prevention of glucocorticoid induced cell death in osteoblasts and the treatment of such conditions as glucocorticoid induced osteoporosis.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: September 7, 2010
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Sylvia Christakos, Yan Liu, Teresita Bellido
  • Adhesive patch for fentanyl administration
    Patent number: 7785622
    Abstract: An adhesive patch for percutaneous fentanyl administration which is easily produced, has long-term continuity, and is excellent in adhesion and conformability to the skin. The adhesive patch comprises a backing layer and a pressure-sensitive adhesive layer formed on one side thereof, wherein the pressure-sensitive adhesive layer comprises fentanyl as an active ingredient, a pressure-sensitive adhesive base, and a tackifier resin, the pressure-sensitive adhesive base comprising polyisobutylene and a styrene/isoprene/styrene block copolymer, the proportion of the polyisobutylene in the adhesive base being, 8 to 15 wt. %, and the ratio of the concentration of the polyisobutylene to that of the styrene/isoprene/styrene block copolymer being from 2:3 to 3:2.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: August 31, 2010
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Takeshi Ito, Tetsuro Tateishi, Naruhito Higo
  • Anti-ADDL antibodies and uses thereof
    Patent number: 7780963
    Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ?1-42.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: August 24, 2010
    Assignees: Merck & Co., Inc., Northwestern University
    Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola
  • Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization
    Patent number: 7776819
    Abstract: Drug delivery is targeted to new opioid receptors using receptor-mediated internalization. Dermorphin was successfully conjugated to DSPE-PEG3400 without affecting the affinity to its receptor. The synthesized conjugate was inserted into preformed sterically stabilized liposomes to obtain dermorphin-grafted SSL. DSPE-PEG34Qo-dermorphin and dermorphin-SSL retained their affinity and selectivity for MOR. Moreover, dermorphin-SSL and encapsulated probes were taken up by CHO-hMOR cells, but not by naive CHO cells or very closely related CHO-hDOR cells. Dermorphin-SSL can be used to deliver drugs to the intracellular component of intended cells with high fidelity. Therefore, dermorphin-SSL is useful to carry pharmaceutical agents to achieve region-specific delivery of analgesics and/or to attenuate side effects associated with opioids.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: August 17, 2010
    Assignee: The Board of Trustees of the University of Illinois
    Inventor: Zaijie Jim Wang
  • Compositions and method for enhancing the therapeutic activity of opiods in treatment of pain
    Patent number: 7763626
    Abstract: Compositions and methods for inhibiting opioid tolerance and opioid withdrawal-induced hyperalgesia are provided.
    Type: Grant
    Filed: May 16, 2005
    Date of Patent: July 27, 2010
    Assignee: Trustees of Dartmouth College
    Inventor: Joyce A. DeLeo
  • Pressure-sensitive adhesive composition and skin patch
    Patent number: 7759400
    Abstract: It is intended to provide a composition which has well-balanced pressure-sensitive adhesiveness and cohesive force as well as favorable application properties to the skin, and a patch which has the above-described characteristics and hardly peels off. This object can be achieved by providing a composition comprising an acrylic copolymer containing from 3 to 25% by weight of hydroxyethyl (meth)acrylate as a constituent, a plasticizer and a pseudo-crosslinking compound, wherein the ratio of the content of the plasticizer to the content of the pseudo-crosslinking compound ranges from 30:1 to 250:1, and a patch.
    Type: Grant
    Filed: January 7, 2005
    Date of Patent: July 20, 2010
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventor: Minoru Kohara
  • Compositions and methods for preventing or treating an inflammatory response
    Patent number: 7754769
    Abstract: The present invention relates to methods for modulating the inflammatory response of respiratory tract cells using an agent that increases ceramide levels in the cells of the respiratory tract.
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: July 13, 2010
    Assignee: McGill University
    Inventors: Stan Kubow, Regina Maria Vilela, Larry Lands
  • Compositions and methods for enhancing the identification of prion protein PrP
    Patent number: 7754865
    Abstract: The present invention provides compositions, methods and kits for enhancing the amplification of PrPsc for use in increasing the sensitivity of identifying the presence of PrPsc in a sample.
    Type: Grant
    Filed: May 5, 2004
    Date of Patent: July 13, 2010
    Assignee: Trustees of Dartmouth College
    Inventors: Surachai Supattapone, Nathan R. Deleault
  • High affinity antibody antagonists of interleukin-13 receptor alpha 1
    Patent number: 7754213
    Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: July 13, 2010
    Assignees: Merck & Co., Inc., CSL Limited
    Inventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
  • Patch with improved anchoring properties between a substrate and an adhesive
    Patent number: 7754236
    Abstract: The present invention relates to a patch which is free from any migration of a drug into a substrate and has favorable anchoring properties between the substrate and adhesive layer, in which the drug containing adhesive layer firmly adheres onto the substrate and which gives no adhesion residue when applied to the skin and then peeled off. Namely, a patch comprising a substrate made of a polyester-based film and a drug-containing adhesive layer laminated thereon wherein the surface roughness (also known as “the central line mean roughness” or “Ra”) of the polyester-based film surface in the side in contact with the adhesive layer is from 0.05 to 0.8 ?m is provided.
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: July 13, 2010
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Tatsuaki Suzuki, Tetsuro Tateishi, Naruhito Higo
  • Method for identifying the sequence of one or more variant nucleotides in a nucleic acid molecule
    Patent number: 7749708
    Abstract: The invention relates to methods for identifying the sequence of one or more variant nucleotides in a nucleic acid molecule. The method involves cleaving a double-stranded nucleic acid molecule containing a mismatch with a mismatch-specific endonuclease which cleaves on the 3? side of the mismatch, and preserving the integrity of the variant nucleotide by ligating a double-stranded linker with a 3?-overhang to said variant nucleotide. Because the variant nucleotide is immediately adjacent to the linker, PCR and/or sequence-by-synthesis analysis can be readily carried out.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: July 6, 2010
    Assignee: Transgenomic, Inc.
    Inventors: Paul D. Taylor, Gary F. Gerard, Reyes Candau
  • Genotyping assay to predict gamma glutamyl hydrolase (GGH) activity
    Patent number: 7741032
    Abstract: Single nucleotide polymorphisms (SNPs) in the gene encoding gamma glutamyl hydrolase (GGH) associated with reduced GGH activity are disclosed. The primary SNP is a change from a cytosine to a thymine at a position corresponding to nucleotide 511 of Genbank sequence accession no. NM 003878. Methods and kits for detecting these SNPs are provided, along with primers useful in detecting these SNP and for amplifying portions of the GGH gene containing these SNPs.
    Type: Grant
    Filed: July 8, 2004
    Date of Patent: June 22, 2010
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: William Edward Evans, Mary Relling, Qing Cheng
  • Method of diagnosing, monitoring, staging, imaging and treating various cancers
    Patent number: 7737255
    Abstract: The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer.
    Type: Grant
    Filed: September 1, 1999
    Date of Patent: June 15, 2010
    Assignee: Diadexus, Inc.
    Inventors: Susana Salceda, Yongming Sun, Herve Recipon, Robert Cafferkey
  • Isolated antibody specific for a mammalian MDM2 binding protein comprising SEQ ID No. 2 or 4
    Patent number: 7732577
    Abstract: Isolated nucleic acid sequences encoding mammalian MDM2 binding protein and polypeptide sequences for the mammalian MDM2 binding protein are provided. Also provided are vectors containing these nucleic acid sequences, host cells which express these proteins and antibodies targeted to these proteins. In addition, methods and compositions for modulating the G1 phase of the cell cycle via altering expression and/or activity of a mammalian MDM2 binding protein are provided.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: June 8, 2010
    Assignee: Philadelphia Health and Education Corporation
    Inventors: Mark Thomas Boyd, Dale Stewart Haines, Nikolina Vlatkovic
  • Anti-ADDL monoclonal antibody and use thereof
    Patent number: 7731962
    Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: June 8, 2010
    Assignee: Merck & Co., Inc.
    Inventors: Gene Kinney, William R. Strohl, Zhiqiang An
  • Modified fuel cells with internal humidification and/or temperature control systems
    Patent number: 7727660
    Abstract: Modified fuel cells with improved distribution of humidity and/or temperature are provided.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: June 1, 2010
    Assignee: IRD Fuel Cells A/S
    Inventors: Henning Frederiksen, Steen Yde-Andersen, Laila Grahl-Madsen, Joergen Schjerning Lundsgaard
  • Methods for reducing T cell responsiveness to an autoantigen with anti-gp39 antibodies and antigen presenting cells
    Patent number: 7722874
    Abstract: Methods for inducing antigen-specific T cell tolerance are disclosed. The methods involve contacting a T cell with: 1) a cell which presents antigen to the T cell, wherein a ligand on the cell interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand on the antigen presenting cell with the receptor on the T cell. In a preferred embodiment, the cell which presents antigen to the T cell is a B cell and the receptor on the surface of the T cell which mediates contact-dependent helper effector function is gp39. Preferably, the antagonist is an anti-gp39 antibody or a soluble gp39 ligand (e.g., soluble CD40). The methods of the invention can be used to induce T cell tolerance to a soluble antigen or to an allogeneic cell.
    Type: Grant
    Filed: October 1, 1998
    Date of Patent: May 25, 2010
    Assignees: Trustees of Dartmouth College, University of Massachusetts Medical Center
    Inventors: Randolph J. Noelle, Teresa M. Foy, Fiona H. Durie
  • Transdermal patch for external use comprising fentanyl
    Patent number: 7718188
    Abstract: A transdermal patch for external use having a backing layer and a pressure-sensitive adhesive layer formed on one surface of the backing layer, which contains polyisobutylene, a mineral oil and fentanyl employed as the active ingredient in the pressure-sensitive adhesive layer and in which the contents of polyisobutylene and fentanyl in the pressure-sensitive adhesive layer respectively range from 75.2 to 94.2% by mass and 1 to 6% by mass while the content of the mineral oil is from 0.25 to 0.05 parts by mass based on polyisobutylene. This patch can be easily produced, has a long-lasting effect and is excellent in adhesion to the skin and tolerability against movement to the body parts.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: May 18, 2010
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Takeshi Ito, Tetsuro Tateishi, Naruhito Higo
  • Methods and kits for separation and detection of proteins in biological samples
    Patent number: 7709193
    Abstract: Methods and kits are provided for separating a mixture of proteins in a biological sample. Methods for detecting and profiling proteins in biological samples by the separation method and kits are also provided. These methods are particularly useful in assessing damage to cells such as cardiac and skeletal muscle cells and in the early clinical diagnosis of myocardial damage by detection of myofilament proteins in serum of a subject.
    Type: Grant
    Filed: May 26, 2005
    Date of Patent: May 4, 2010
    Assignee: Queen's University at Kingston
    Inventors: Jennifer E. Van Eyk, Jeremy A. C. Simpson
  • Non-immunostimulatory antibody and compositions containing the same
    Patent number: 7700099
    Abstract: The present invention relates to a non-immunostimulatory antibody which lacks antibody-dependent cell-mediated cytotoxicity, Fc gamma receptor binding and complement-mediated cytotoxicity. In some embodiments, the antibody contains a modified immunoglobulin G2 (IgG2) Fc region with at least one substitution in the B/C loop, FcRn binding domain, and the F/G loop. The antibody of the invention is useful in the preparation of therapeutic antibodies and pharmaceutical compositions and kits containing the same.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: April 20, 2010
    Assignee: Merck & Co., Inc.
    Inventor: William R. Strohl